COVID-19 Vaccine Second Booster Authorization A ‘Stopgap Measure,’ US FDA’s Marks Says

CBER director says agency understands 'we simply can't be boosting people as frequently as we are,' but wants to give older and immunocompromised individuals extra protection now while FDA considers whether and when formulations should be modified ahead of an expected surge this fall.

COVID vaccine booster
A "stopgap measure" is how FDA's Peter Marks described the recent authorization of a second COVID-19 vaccine booster dose. • Source: Alamy

The US Food and Drug Administration’s recent authorization of a second COVID-19 vaccine booster dose in certain populations was a “stopgap measure” until plans are in place for a potentially new formulation ahead of an expected case surge next winter, Center for Biologics Evaluation and Research director Peter Marks said.

On 29 March, the FDA authorized a second booster of the Pfizer Inc./BioNTech SE and Moderna, Inc.'s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers